Anderson-Fabry Disease (AFD)
Details
Anderson–Fabry disease (AFD) is a rare X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to deficiency or dysfunction of the enzyme alpha-galactosidase A (α-Gal A). This results in progressive accumulation of globotriaosylceramide (Gb3) and its deacylated catabolite globotriaosylsphingosine (Lyso-Gb3) in the lysosomes of multiple tissues. Progressive organ involvement — particularly cardiac, renal, and neurological — causes reduced quality of life and life expectancy, with cardiac involvement representing the main cause of morbidity and mortality in both sexes. AFD accounts for 0.5–1% of all HCM diagnoses and is found in approximately 0.9% of patients with LVH in screening programmes. (sources/fabry-ehj-2024, rating: high; sources/esc-cmp-2023, rating: very high)
Key Facts
Genetics and Molecular Basis
- Gene: GLA (Xq22.1) — X-linked; males are hemizygous; females are heterozygous (variable phenotype due to X-inactivation).
- Enzyme: α-galactosidase A (α-Gal A) — responsible for cleavage of Gb3 from glycolipids in the lysosome.
- Genotype–phenotype correlation:
- Large deletions, frameshift, stop codons, consensus splicing lesions → classic phenotype
- Missense variants (~60% of GLA variants): may be benign (R118C, S126G, A143T, D313Y), classic (R227X, R363H), or late-onset (N215S — Europe/North America; F113L — Portugal; IVS4+919G>A — China/Taiwan)
- Genetic variants of unknown significance (GVUS): Prevalent in screening settings; pathogenicity requires integration of genetic, metabolic, clinical, and histological data; periodic reassessment with geneticists recommended. (sources/fabry-ehj-2024, rating: high)
Clinical Phenotypes
- Classic AFD (predominantly males):
- α-Gal A activity <3% of normal; Lyso-Gb3 markedly elevated
- Paediatric onset: acroparesthesias (neuropathic pain), angiokeratomas, cornea verticillata, GI symptoms, anhidrosis, heat intolerance
- 2nd–4th decade: progressive cardiac, renal, and cerebral involvement
- Late-onset AFD (non-classic):
- Residual α-Gal A activity; Lyso-Gb3 elevated but lower than classic
- Predominantly single-organ (typically cardiac) involvement in adulthood
- Absent or variable classic systemic features; severity of cardiac involvement not significantly different from classic males
- Female heterozygotes:
- Phenotype ranges from asymptomatic to as severe as affected males
- Determined largely by X-chromosome inactivation skewness and epigenetic factors (DNA methylation, histone modifications, microRNAs, lncRNAs)
- Generally milder with later occurrence of organ damage; enzyme activity may be normal → genetic testing mandatory
- (sources/fabry-ehj-2024, rating: high)
Epidemiology
- Classic AFD prevalence: ~1:40,000 males historically; late-onset ~1:1,200–1:3,000 in newborn screenings (varies by region)
- ~1% of renal dialysis, cardiac, and stroke clinic patients have undiagnosed AFD
- UK Biobank (n=200,643): pathogenic variants for classic AFD 1:200,643; late-onset 1:5,732 (sources/fabry-ehj-2024, rating: high)
Diagnosis
- Males: α-Gal A activity in leucocytes or dry blood spot (diagnostic); confirm with GLA genetic testing
- Females: Enzyme activity may be normal → GLA genetic testing mandatory
- Lyso-Gb3 (plasma): Elevated in pathogenic variants; used to distinguish pathogenic from benign GVUS; monitored on treatment
- Cardiac CMR red flags: Basal-inferolateral LGE + reduced native T1 values (reflects Gb3 myocardial storage, not fibrosis — pathognomonic combination). (sources/esc-cmp-2023, rating: very high; sources/fabry-ehj-2024, rating: high)
- Echocardiographic red flags: Concentric biventricular hypertrophy, disproportionate papillary muscle hypertrophy, AV valve thickening, reduced GLS. (sources/esc-cmp-2023, rating: very high)
- ECG red flags (early): Short P-wave duration, short PQ interval, prolonged R-wave peak time — pre-LVH markers. (sources/fabry-ehj-2024, rating: high)
- Extracardiac red flags: Neuropathic pain, angiokeratomas, cornea verticillata, albuminuria, hypohidrosis, GI symptoms, hearing loss, no male-to-male transmission. (sources/esc-cmp-2023, rating: very high)
- Endomyocardial biopsy (EM): Reserved for strong suspicion with uncertain GVUS; lamellar inclusions (Gb3-laden myocytes) on electron microscopy. (sources/esc-cmp-2023, rating: very high)
- Screening: HCM/unexplained LVH populations → AFD prevalence 0.5–4% depending on criteria.
- Diagnostic delay: Average 14 years from symptom onset to diagnosis — unchanged in recent registry data. (sources/fabry-ehj-2024, rating: high)
Cardiac Involvement — See concepts/Fabry-Cardiomyopathy
- HCM genocopy: biventricular concentric hypertrophy with papillary muscle prominence
- HFpEF dominant HF phenotype: 40% of AFD patients by ESC criteria; 91% of these are HFpEF
- Coronary microvascular dysfunction; MINOCA (common early presentation, especially females)
- Arrhythmias: VT, AF, sinus bradycardia, AV conduction disturbances
- CMR staging: Stage 1 (reduced T1 only) → Stage 2 (LVH + T2/LGE) → Stage 3 (extensive LGE + thinning) → Stage 4 (systolic dysfunction)
- (sources/fabry-ehj-2024, rating: high)
Conduction Disorders in Fabry Disease
- Short PR interval is an early conduction finding in AFD, reflecting glycosphingolipid deposition in the AV node region and accessory pathways; this precedes progressive AVB.
- Conduction tissue fibrosis and infiltration → more advanced AVB in later disease stages.
- 6% of young patients with Anderson–Fabry disease require bradyarrhythmia devices — making AFD a clinically relevant cause of conduction disease in young adults evaluated for unexplained CCD. (sources/conduction-disorders-jaha-2025, rating: high)
- Device selection for symptomatic bradycardia with LVEF ≤35%: ICD or CRT-D preferred over pacemaker alone in AFD (and Danon disease), given SCD risk from the underlying cardiomyopathy. (sources/conduction-disorders-jaha-2025, rating: high)
- CMR ECG-gating in Fabry disease: The presence of LBBB can cause artifacts in T1 mapping due to mechanical dyssynchrony; manual correction of endocardial/epicardial contours required to maintain T1 mapping accuracy. (sources/conduction-disorders-jaha-2025, rating: high)
Disease-Specific Treatment
Enzyme Replacement Therapy (ERT)
- Agalsidase alfa 0.2 mg/kg IV q2w (EMA); agalsidase beta 1.0 mg/kg IV q2w (EMA + FDA from age 2)
- Pegunigalsidase alfa (PEGylated) 1.0 mg/kg IV q2w — FDA/EMA approved 2023; reduced immunogenicity; non-inferior to agalsidase beta
- Indicated in all males with classic disease at any age, regardless of symptoms; in late-onset/females, initiate at earliest signs of organ involvement
- Early initiation critical — limited efficacy in advanced irreversible disease
- Cost ~€300,000/year; anti-drug antibodies (ADAs) can limit ERT efficacy
- (sources/fabry-ehj-2024, rating: high; sources/esc-cmp-2023, rating: very high)
Pharmacologic Chaperone (Migalastat)
- Oral, q48h; for patients ≥12 years with eGFR >30 and amenable GLA variants
- ~60% of GLA missense variants are in vitro amenable; in vitro amenability ≠ in vivo response in some variants
- EMA-approved 2016; FDA-approved 2018
- (sources/fabry-ehj-2024, rating: high)
Emerging Therapies
- Substrate reduction therapy (lucerastat, venglustat): failed in trials to date; research ongoing
- Gene therapy (AAV2/6 — isaralgagene civaparvovec): Phase 1/2 (n=13) — supraphysiologic enzyme levels; 5 patients ceased ERT; Phase 3 pending. Safety concern: separate trial on FDA clinical hold (atypical HUS, renal vessel thrombosis)
- mRNA therapy, siRNA nanoparticle SRT, iPSC-based strategies: preclinical
- (sources/fabry-ehj-2024, rating: high)
Cardiac Management (Key Specific Points)
- SGLT2 inhibitors — should be considered for HFpEF (Class I ESC); may also benefit AFD nephropathy
- Cardiac myosin inhibitors (mavacamten) — must NOT be used in AFD (approved only for sarcomeric obstructive HCM)
- HCM Risk-SCD calculator — must NOT be used in AFD (not validated)
- Amiodarone — contraindicated in AFD: interferes with lysosomal function, worsens enzymatic deficiency, impairs ERT/migalastat efficacy
- Prefer DOACs over warfarin to minimise cerebral microbleed risk and warfarin nephropathy
- ICD primary prevention: consider in massive LVH + extensive LGE, especially with syncope, NSVT, or pacing indication
- (sources/fabry-ehj-2024, rating: high; sources/esc-cmp-2023, rating: very high)
Female Fabry Disease — Reframing as X-Linked Dominant
- Female patients with AFD should be regarded as patients, not carriers — unlike Hunter syndrome (also X-linked lysosomal) where females are genuinely rare.
- Some experts argue AFD should be classified as X-linked dominant, given frequency and severity of disease in females.
- Phenotype ranges from severe (cardiac transplantation in some cases) to asymptomatic; severity determined largely by X-inactivation skewness and epigenetic factors.
- Mean age of death in female Fabry patients: 55.4 years — a major and underappreciated mortality burden.
- Female patients often face delayed access to treatment from underdiagnosis across the wide phenotypic spectrum.
- (sources/fabry-pcvd-2025, rating: medium)
Quality of Life and Fatigue
- Chronic fatigue is prevalent and debilitating regardless of disease severity or treatment status.
- Key finding: Fatigue in AFD results primarily from alterations in skeletal muscle energy metabolism (miR-17/Warburg effect) — not from cardiac failure. This is counterintuitive and has management implications.
- Additional burdens: neuropathic pain, GI disturbances, depression, thermoregulatory abnormalities.
- QoL deficits persist even on ERT or chaperone therapy → comprehensive psychosocial support is essential.
- (sources/fabry-pcvd-2025, rating: medium)
Multidisciplinary Team
- Core: cardiologist, nephrologist, neurologist, geneticist, paediatrician + multiple cardiology subspecialties
- Dedicated AFD referral centres reduce diagnostic delay; MetabERN facilitates European cross-border access
- (sources/fabry-ehj-2024, rating: high)
Contradictions / Open Questions
- Diagnostic delay unchanged: Average 14 years despite advances in diagnostics. Newborn screening may change this, but raises ethical dilemmas for late-onset variants (when to treat, decade-long prodrome). (sources/fabry-ehj-2024, rating: high)
- ERT timing — when does irreversibility begin? ERT has limited efficacy in advanced disease with irreversible organ damage, but no validated staging system precisely defines when irreversibility begins. Heterogeneous prescribing practice results. (sources/esc-cmp-2023, rating: very high)
- Migalastat amenability discrepancy: In vitro amenability ≠ in vivo treatability in a subset; assay variability between laboratories; some 'amenable' variants require further clinical evidence. (sources/fabry-ehj-2024, rating: high)
- AFD HCM mimicry — misuse of HCM tools: With ~0.9% of LVH patients having AFD, a proportion receiving HCM-directed therapies (mavacamten, HCM Risk-SCD) may have undiagnosed AFD. Pre-treatment α-galactosidase screening is underimplemented. (sources/esc-cmp-2023, rating: very high)
- Late-onset treatment evidence: ERT/migalastat efficacy data in late-onset AFD are weak; most evidence derived from mixed classic/late-onset cohorts. (sources/fabry-ehj-2024, rating: high)
- Cost vs. benefit in advanced disease: At ~€300,000/year, active debate exists on whether to continue disease-specific therapy in patients with irreversible organ damage. (sources/fabry-ehj-2024, rating: high)
- ERT may worsen cardiac fibrosis — the ERT paradox: A meta-analysis of 11 cardiac MRI studies showed ERT augmented LGE (increased myocardial fibrosis). Histological data from patients on ERT ≥18 months revealed cardiomyocyte disarray, severe vacuolisation, cell death, and fibrosis. Heart disease remains the most common cause of death in Fabry disease despite ERT. Whether this reflects disease progression, ERT-related direct harm, or selection bias is unresolved. (sources/fabry-pcvd-2025, rating: medium)
- Animal model failure limits preclinical research: GLA-KO rodents have no cardiac phenotype — compensatory upregulation of α-galactosidase B (NAGA/GALB) and GLB1 metabolise Gb3, preventing accumulation. Other transgenic models also fail to replicate human Fabry cardiomyopathy. This is a major bottleneck for therapeutic development. (sources/fabry-pcvd-2025, rating: medium)
- Female AFD mortality underappreciated: Mean age of death 55.4 years in females; some experts argue AFD is X-linked dominant rather than recessive. Female patients are frequently undertreated due to underdiagnosis. (sources/fabry-pcvd-2025, rating: medium)
Connections
- Related to sources/conduction-disorders-jaha-2025
- Related to concepts/Conduction-Disorders-in-Young-Adults
- Related to concepts/Fabry-Cardiomyopathy
- Related to concepts/HFpEF — AFD as genetic cause of HFpEF
- Related to concepts/Phenotypic-Approach-to-Cardiomyopathy — AFD is a key HCM genocopy
- Related to concepts/Late-Gadolinium-Enhancement — inferolateral LGE pattern; low native T1
- Related to concepts/LVOTO — uncommon; myosin inhibitors contraindicated
- Related to concepts/HCM-Risk-SCD — not applicable to AFD
- Related to concepts/AAV-Gene-Delivery — AAV2/6 gene therapy in Phase 1/2
- Related to entities/Amiodarone — contraindicated in AFD
- Related to entities/HCM — HCM genocopy differential
- Related to entities/Heart-Failure
- Related to sources/fabry-ehj-2024
- Related to sources/fabry-pcvd-2025
- Related to sources/esc-cmp-2023